NCT07313176Terminated
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
A Prospective, Non-Interventional Study on the Long-term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIGON®) in Patients With Parkinson's Disease Previously Treated With Subcutaneous Foslevodopa in Routine Care
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part IV (MDS-UPDRS IV).
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 1 (actual)
- First submitted
- 17 Dec 2025
- Start date
- 8 May 2026
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Britannia Pharmaceuticals Ltd.
- Diseases
- Parkinson disease
- NCT number
- NCT07313176
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who will not be seen again for their follow up care at the investigator's site after commencement of LECIGON® therapy
Other illness
- Participants with anticipated pump placement or pump use issues, e.g. participants with acute severe illness, participants unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse
Other
- Participants with contraindications as defined in the current version of the SmPC for LECIGON®
- Participants taking part in a clinical (interventional) trial at the same time
Who the study is looking for
- Adult participants (18 years old and over) with advanced Parkinson's disease with severe motor fluctuations and dyskinesia
- Participants for whom the treating physician has made the decision to initiate treatment with LECIGON® in accordance with the Summary of Product Characteristics (SmPC)
- Participants must have had previous treatment with subcutaneous foslevodopa (foslevodopa-foscarbidopa) for a minimum of 1 month
- Participants or legal representative must have signed informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asklepios Fachklinikum Stadtroda GmbH Coordinator of this site? Confirm its status | Stadtroda | Germany | Unknown status |
| Complejo Hospitalario Universitario de A Coruña (CHUAC) Coordinator of this site? Confirm its status | A Coruña | Spain | Unknown status |
| National Hospital For Neurology and Neurosurgery Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Newcastle Upon Tyne Hospitals NHS Foundation Trust Coordinator of this site? Confirm its status | Newcastle upon Tyne | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.